Focused On-demand Library for Intraflagellar transport protein 81 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8WYA0

UPID:

IFT81_HUMAN

Alternative names:

Carnitine deficiency-associated protein expressed in ventricle 1

Alternative UPACC:

Q8WYA0; Q2YDY1; Q8NB51; Q9BSV2; Q9UNY8

Background:

Intraflagellar transport protein 81 homolog (IFT81) is a crucial component of the intraflagellar transport complex B, playing a pivotal role in ciliogenesis and the regulation of SHH signaling. It forms a tubulin-binding module with IFT74, essential for the transport of tubulin within the cilium. IFT81's involvement in spermatogenesis, through the modulation of sperm flagella assembly and elongation, highlights its significance in cellular and developmental processes.

Therapeutic significance:

IFT81's association with Short-rib thoracic dysplasia 19, a condition marked by skeletal abnormalities and potential polydactyly, underscores its therapeutic potential. Understanding the role of IFT81 could open doors to potential therapeutic strategies for treating ciliopathies and improving outcomes for affected individuals.